Silex Systems (SLX) Investor presentation summary
Event summary combining transcript, slides, and related documents.
Investor presentation summary
24 Feb, 2026Commercialisation strategy and technology highlights
SILEX laser enrichment technology offers higher efficiency and throughput than centrifuge methods, aiming for lower costs and classified under strict government security in Australia and the US.
GLE, a US-based JV (51% Silex, 49% Cameco), holds exclusive rights to commercialise SILEX technology, with Silex earning perpetual royalties of 7–12% on enrichment revenues.
Key technology demonstration (TRL-6) was completed in October 2025, de-risking the path to commercialisation and enabling progress to full-scale plant design.
GLE secured a 700-acre site in Paducah, KY, adjacent to DOE's former plant, with exclusive access to 150 million pounds of uranium tails for up to 30 years of feedstock.
US DOE awarded GLE up to $28.5m in January 2026 to advance next-generation enrichment technology.
Market opportunity and industry context
The US nuclear industry is experiencing a renaissance, with 94 reactors and strong public and private support, but remains heavily reliant on imported uranium and enrichment services.
Recent legislation, including the Prohibiting Russian Uranium Imports Act (2024), is driving demand for domestic supply solutions, with Russian imports banned from 2028.
Global nuclear fuel markets have tightened, with uranium, conversion, and enrichment prices rising 100–200% since 2022 due to geopolitical tensions and supply chain disruptions.
Forecasts show uncovered US uranium demand exceeding 25 million lbs annually from 2030, and enrichment demand rising to 14 million SWU by 2035.
GLE’s PLEF project is positioned as a single-site solution for US uranium, conversion, and enrichment, addressing critical supply chain vulnerabilities.
Financial and operational outlook
PLEF aims to produce up to 5 million lbs of natural uranium and 2 million kg of conversion capacity per year, with potential annual revenues of $450m (uranium) and $110m (conversion) at current prices.
Initial LEU production could reach 2 million SWU/year, expandable to 6 million SWU/year, with potential revenue of $350m/year at current SWU prices.
Silex’s equity in GLE and perpetual royalty structure provide dual value streams, with Cameco holding an option to increase its stake by 26% before April 2028.
As of December 2025, Silex held $200m in cash and term deposits, with no corporate debt.
Latest events from Silex Systems
- Revenue doubled and cash surged after a capital raise; GLE secured a major U.S. DOE award.SLX
H1 202624 Feb 2026 - Nuclear and quantum projects advanced, with strong cash reserves and key risks addressed.SLX
AGM 20243 Feb 2026 - Robust financials and tech milestones drive strategic growth in nuclear and silicon sectors.SLX
AGM 20253 Feb 2026 - Major technology milestone and US support position SILEX for uranium and quantum silicon growth.SLX
Investor Presentation9 Nov 2025 - Net loss widened to $42.6m as SILEX technology nears commercial readiness; strong cash raised.SLX
H2 202526 Aug 2025 - $145m equity raise funds SILEX laser enrichment commercialisation, targeting US nuclear fuel supply.SLX
Investor Presentation7 Aug 2025 - GLE's SILEX technology is on track for commercialisation, targeting major US nuclear fuel supply gaps.SLX
Investor Presentation30 Jun 2025 - GLE pilot and Silex's diversification position the company for growth amid nuclear market shifts.SLX
H2 202413 Jun 2025 - GLE accelerates SILEX technology for uranium, silicon, and isotope markets, targeting 2028 launch.SLX
Investor Presentation13 Jun 2025